Unfairness to Patients With Alzheimer Disease in Medicare’s Coverage of Antiamyloid Immunotherapy-Reference-Cited by-同舟云学术

Unfairness to Patients With Alzheimer Disease in Medicare’s Coverage of Antiamyloid Immunotherapy

Published:2022-10-01 Issue:10 Volume:79 Page:962
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Stern Andrew M.¹,Selkoe Dennis J.¹

Affiliation:

1. Ann Romney Center for Neurologic Diseases, Division of Cognitive and Behavioral Neurology, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Abstract

This Viewpoint discusses the US Center for Medicare and Medicaid Services’ decision on aducanumab, a drug that can treat Alzheimer disease.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2794925/jamaneurology_stern_2022_vp_220009_1664471607.54408.pdf

Reference6 articles.

1. Two randomized phase 3 studies of aducanumab in early alzheimer’s disease.;Budd Haeberlein;J Prev Alzheimers Dis,2022

2. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.;Karran;Nat Rev Drug Discov,2022

3. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aß protofibril antibody.;Swanson;Alzheimers Res Ther,2021

4. Donanemab in early Alzheimer’s disease.;Mintun;N Engl J Med,2021

5. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease.;Salloway;Nat Med,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials;Age and Ageing;2024-02-01

2. Anti‐dementia bias and Medicare regulation of Alzheimer's disease care;Alzheimer's & Dementia;2023-05-24

3. Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics;Drugs;2023-04-15

4. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development;The Lancet Regional Health - Americas;2023-04

5. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease;Neurology and Therapy;2023-03-18